Discover and read the best of Twitter Threads about #PharmEasy
Most recents (4)
🚨Welcome to a new edition of #FullStack by @samidhas, a place where you’ll find unfiltered commentary on all things technology. Read on 👇
#Edtech major #Byju's is faced with a trifecta of issues. There is the $1.2 billion TLB (term loan B), delayed audited results, and an equity funding round which has been in the works for months now
On Tuesday, #Byju’s defaulted on interest payment of $40 million for its term loan. That was not all, the beleaguered edtech firm said it is suing hedge fund Redwood, one of its lenders.
economictimes.indiatimes.com/tech/technolog…
economictimes.indiatimes.com/tech/technolog…
Dr. Velumani onboard with 5% .
Aditya Puri inducted into the board and my guess will me made Chairman soon .
Founder( Siddharth Shah’s ) parents have tasted failure & succeeded.
FY22 Revenue : 6500 Cr.
Peak of Pessimism priced in ? Mostly.
#UL2
Aditya Puri inducted into the board and my guess will me made Chairman soon .
Founder( Siddharth Shah’s ) parents have tasted failure & succeeded.
FY22 Revenue : 6500 Cr.
Peak of Pessimism priced in ? Mostly.
#UL2
IPO only when it’s just 3-6 months away from hitting EBITDA Positive .
This one is a B2B + B2C + B2B2C bet .
Also it’s Diagnostics arm is smartly playing the Tier 3 & Tier 4 - BHARAT 🇮🇳 theme .
#Thyrocare #Pharmeasy
This one is a B2B + B2C + B2B2C bet .
Also it’s Diagnostics arm is smartly playing the Tier 3 & Tier 4 - BHARAT 🇮🇳 theme .
#Thyrocare #Pharmeasy
My Scuttlebutt revealed peak of TECH employee firing done by last December . Now realistic numbers have settled in .
Definitely 2022 has been a year of reevaluation ( maybe all thanks to Zomato, Nykaa & PolicyBazaars of the world)
$9 BN. to $6 BN. to where ? 😃
Definitely 2022 has been a year of reevaluation ( maybe all thanks to Zomato, Nykaa & PolicyBazaars of the world)
$9 BN. to $6 BN. to where ? 😃
Pharmeasy IPO (API Holdings IPO)
#pharmeasy #apiholdings #pharmeasyipo
A thread on the key takeaways from DHRP .....
IPO expected in Feb 2021
investmentbank.kotak.com/downloads/api-…
#pharmeasy #apiholdings #pharmeasyipo
A thread on the key takeaways from DHRP .....
IPO expected in Feb 2021
investmentbank.kotak.com/downloads/api-…
The parent company of PharmEasy, API Holdings, has filed for its DRHP with SEBI on 08th Nov for a fresh issue of ₹6,250cr ($830m) value equity shares and there is no offer for sale (OFS) by the promoters.
They are also looking for a pre-IPO placement of ₹1,250 cr in this issue
They are also looking for a pre-IPO placement of ₹1,250 cr in this issue
Objectives of the issue
1. Repay its outstanding debt of ₹1,930cr
2. Fund organic growth initiatives ₹1,260cr (marketing and promotional activities, supply chain and ramp up technology infra)
3. Fund inorganic growth initiatives ₹1,500cr
4. Corporate purposes ₹1,560cr
1. Repay its outstanding debt of ₹1,930cr
2. Fund organic growth initiatives ₹1,260cr (marketing and promotional activities, supply chain and ramp up technology infra)
3. Fund inorganic growth initiatives ₹1,500cr
4. Corporate purposes ₹1,560cr
#Pharmeasy - Health Tech #unicorn – to acquire Majority stake (66%) in #Thyrocare. Open offer for an additional 26% stake at Rs1300/sh. With this diagnostics bet, it completes its exhaustive portfolio of "Wholistic Outpatient Healthcare Ecosystem". (1/9)
Gujju Gang from Ghatkopar (as founders call themselves) make it big in what is first-ever acquisition of publicly listed firm by the unicorn. New funding tied up at #valuations of USD4bn. Promoters of Thyrocare will also be investing in Pharmeasy for 5% stake. (2/9)
Pharmeasy founders started as venture called dialhealth.com (2012-13) which failed, followed by Dial Health chain of retail stores which also failed. After 2 failed ventures, they moved to distribution business (& B2B) that was a success (2015). (3/9)
